Joint clinical assessments (JCAs) are one of the most important elements of the EU Health Technology Assessment (HTA) Regulation, which will enter into force from January 2025, initially for new cancer medicines and advanced therapy medicinal products that are granted marketing authorizations by the European Commission.
The Member State Coordination Group on HTA (HTA CG), which was established under the new regulation, recently adopted two guidance...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?